

REMARKS


In the outstanding Office Action, the Examiner required that Applicants elect for prosecution one of the inventions among Groups 1-128.

In response, Applicants hereby elect to prosecute initially the invention of Group 7, namely Claims 1-3, 5, 7, 10-13, 18 and 19, drawn to DNA related to IgA nephropathy as set forth in SEQ ID NO:7.

Entry hereof is earnestly solicited.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our below listed address.

Respectfully submitted,



\_\_\_\_\_  
Attorney for Applicants  
Frank A. DeLucia  
Registration No. 42,476

FITZPATRICK, CELLA, HARPER & SCINTO  
30 Rockefeller Plaza  
New York, New York 10112-3801  
Facsimile: (212) 218-2200

NY\_MAIN 401311v1